Cargando…
Co-Delivery of Letrozole and Cyclophosphamide via Folic Acid-Decorated Nanoniosomes for Breast Cancer Therapy: Synergic Effect, Augmentation of Cytotoxicity, and Apoptosis Gene Expression
Breast cancer is one of the most prevalent causes of cancer mortality in women. In order to increase patient prognosis and survival rates, new technologies are urgently required to deliver therapeutics in a more effective and efficient manner. Niosome nanoparticles have been recently employed as the...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8780158/ https://www.ncbi.nlm.nih.gov/pubmed/35056063 http://dx.doi.org/10.3390/ph15010006 |
_version_ | 1784637766403883008 |
---|---|
author | Sahrayi, Hamidreza Hosseini, Elham Karimifard, Sara Khayam, Nazanin Meybodi, Seyed Mohammadmahdi Amiri, Sahar Bourbour, Mahsa Farasati Far, Bahareh Akbarzadeh, Iman Bhia, Mohammed Hoskins, Clare Chaiyasut, Chaiyavat |
author_facet | Sahrayi, Hamidreza Hosseini, Elham Karimifard, Sara Khayam, Nazanin Meybodi, Seyed Mohammadmahdi Amiri, Sahar Bourbour, Mahsa Farasati Far, Bahareh Akbarzadeh, Iman Bhia, Mohammed Hoskins, Clare Chaiyasut, Chaiyavat |
author_sort | Sahrayi, Hamidreza |
collection | PubMed |
description | Breast cancer is one of the most prevalent causes of cancer mortality in women. In order to increase patient prognosis and survival rates, new technologies are urgently required to deliver therapeutics in a more effective and efficient manner. Niosome nanoparticles have been recently employed as therapeutic platforms capable of loading and carrying drugs within their core for both mono and combination therapy. Here, niosome-based nanoscale carriers were investigated as a targeted delivery system for breast cancer therapy. The platform developed consists of niosomes loaded with letrozole and cyclophosphamide (NLC) and surface-functionalized with a folic-acid-targeting moiety (NLCPFA). Drug release from the formulated particles exhibited pH-sensitive properties in which the niosome showed low and high release in physiological and cancerous conditions, respectively. The results revealed a synergic effect in cytotoxicity by co-loading letrozole and cyclophosphamide with an efficacy increment in NLCPFA use in comparison with NLC. The NLCPFA resulted in the greatest drug internalization compared to the non-targeted formulation and the free drug. Additionally, downregulation of cyclin-D, cyclin-E, MMP-2, and MMP-9 and upregulating the expression of caspase-3 and caspase-9 genes were observed more prominently in the nanoformulation (particularly for NLCPFA) compared to the free drug. This exciting data indicated that niosome-based nanocarriers containing letrozole and cyclophosphamide with controlled release could be a promising platform for drug delivery with potential in breast cancer therapy. |
format | Online Article Text |
id | pubmed-8780158 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-87801582022-01-22 Co-Delivery of Letrozole and Cyclophosphamide via Folic Acid-Decorated Nanoniosomes for Breast Cancer Therapy: Synergic Effect, Augmentation of Cytotoxicity, and Apoptosis Gene Expression Sahrayi, Hamidreza Hosseini, Elham Karimifard, Sara Khayam, Nazanin Meybodi, Seyed Mohammadmahdi Amiri, Sahar Bourbour, Mahsa Farasati Far, Bahareh Akbarzadeh, Iman Bhia, Mohammed Hoskins, Clare Chaiyasut, Chaiyavat Pharmaceuticals (Basel) Article Breast cancer is one of the most prevalent causes of cancer mortality in women. In order to increase patient prognosis and survival rates, new technologies are urgently required to deliver therapeutics in a more effective and efficient manner. Niosome nanoparticles have been recently employed as therapeutic platforms capable of loading and carrying drugs within their core for both mono and combination therapy. Here, niosome-based nanoscale carriers were investigated as a targeted delivery system for breast cancer therapy. The platform developed consists of niosomes loaded with letrozole and cyclophosphamide (NLC) and surface-functionalized with a folic-acid-targeting moiety (NLCPFA). Drug release from the formulated particles exhibited pH-sensitive properties in which the niosome showed low and high release in physiological and cancerous conditions, respectively. The results revealed a synergic effect in cytotoxicity by co-loading letrozole and cyclophosphamide with an efficacy increment in NLCPFA use in comparison with NLC. The NLCPFA resulted in the greatest drug internalization compared to the non-targeted formulation and the free drug. Additionally, downregulation of cyclin-D, cyclin-E, MMP-2, and MMP-9 and upregulating the expression of caspase-3 and caspase-9 genes were observed more prominently in the nanoformulation (particularly for NLCPFA) compared to the free drug. This exciting data indicated that niosome-based nanocarriers containing letrozole and cyclophosphamide with controlled release could be a promising platform for drug delivery with potential in breast cancer therapy. MDPI 2021-12-21 /pmc/articles/PMC8780158/ /pubmed/35056063 http://dx.doi.org/10.3390/ph15010006 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Sahrayi, Hamidreza Hosseini, Elham Karimifard, Sara Khayam, Nazanin Meybodi, Seyed Mohammadmahdi Amiri, Sahar Bourbour, Mahsa Farasati Far, Bahareh Akbarzadeh, Iman Bhia, Mohammed Hoskins, Clare Chaiyasut, Chaiyavat Co-Delivery of Letrozole and Cyclophosphamide via Folic Acid-Decorated Nanoniosomes for Breast Cancer Therapy: Synergic Effect, Augmentation of Cytotoxicity, and Apoptosis Gene Expression |
title | Co-Delivery of Letrozole and Cyclophosphamide via Folic Acid-Decorated Nanoniosomes for Breast Cancer Therapy: Synergic Effect, Augmentation of Cytotoxicity, and Apoptosis Gene Expression |
title_full | Co-Delivery of Letrozole and Cyclophosphamide via Folic Acid-Decorated Nanoniosomes for Breast Cancer Therapy: Synergic Effect, Augmentation of Cytotoxicity, and Apoptosis Gene Expression |
title_fullStr | Co-Delivery of Letrozole and Cyclophosphamide via Folic Acid-Decorated Nanoniosomes for Breast Cancer Therapy: Synergic Effect, Augmentation of Cytotoxicity, and Apoptosis Gene Expression |
title_full_unstemmed | Co-Delivery of Letrozole and Cyclophosphamide via Folic Acid-Decorated Nanoniosomes for Breast Cancer Therapy: Synergic Effect, Augmentation of Cytotoxicity, and Apoptosis Gene Expression |
title_short | Co-Delivery of Letrozole and Cyclophosphamide via Folic Acid-Decorated Nanoniosomes for Breast Cancer Therapy: Synergic Effect, Augmentation of Cytotoxicity, and Apoptosis Gene Expression |
title_sort | co-delivery of letrozole and cyclophosphamide via folic acid-decorated nanoniosomes for breast cancer therapy: synergic effect, augmentation of cytotoxicity, and apoptosis gene expression |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8780158/ https://www.ncbi.nlm.nih.gov/pubmed/35056063 http://dx.doi.org/10.3390/ph15010006 |
work_keys_str_mv | AT sahrayihamidreza codeliveryofletrozoleandcyclophosphamideviafolicaciddecoratednanoniosomesforbreastcancertherapysynergiceffectaugmentationofcytotoxicityandapoptosisgeneexpression AT hosseinielham codeliveryofletrozoleandcyclophosphamideviafolicaciddecoratednanoniosomesforbreastcancertherapysynergiceffectaugmentationofcytotoxicityandapoptosisgeneexpression AT karimifardsara codeliveryofletrozoleandcyclophosphamideviafolicaciddecoratednanoniosomesforbreastcancertherapysynergiceffectaugmentationofcytotoxicityandapoptosisgeneexpression AT khayamnazanin codeliveryofletrozoleandcyclophosphamideviafolicaciddecoratednanoniosomesforbreastcancertherapysynergiceffectaugmentationofcytotoxicityandapoptosisgeneexpression AT meybodiseyedmohammadmahdi codeliveryofletrozoleandcyclophosphamideviafolicaciddecoratednanoniosomesforbreastcancertherapysynergiceffectaugmentationofcytotoxicityandapoptosisgeneexpression AT amirisahar codeliveryofletrozoleandcyclophosphamideviafolicaciddecoratednanoniosomesforbreastcancertherapysynergiceffectaugmentationofcytotoxicityandapoptosisgeneexpression AT bourbourmahsa codeliveryofletrozoleandcyclophosphamideviafolicaciddecoratednanoniosomesforbreastcancertherapysynergiceffectaugmentationofcytotoxicityandapoptosisgeneexpression AT farasatifarbahareh codeliveryofletrozoleandcyclophosphamideviafolicaciddecoratednanoniosomesforbreastcancertherapysynergiceffectaugmentationofcytotoxicityandapoptosisgeneexpression AT akbarzadehiman codeliveryofletrozoleandcyclophosphamideviafolicaciddecoratednanoniosomesforbreastcancertherapysynergiceffectaugmentationofcytotoxicityandapoptosisgeneexpression AT bhiamohammed codeliveryofletrozoleandcyclophosphamideviafolicaciddecoratednanoniosomesforbreastcancertherapysynergiceffectaugmentationofcytotoxicityandapoptosisgeneexpression AT hoskinsclare codeliveryofletrozoleandcyclophosphamideviafolicaciddecoratednanoniosomesforbreastcancertherapysynergiceffectaugmentationofcytotoxicityandapoptosisgeneexpression AT chaiyasutchaiyavat codeliveryofletrozoleandcyclophosphamideviafolicaciddecoratednanoniosomesforbreastcancertherapysynergiceffectaugmentationofcytotoxicityandapoptosisgeneexpression |